Loading...
XNASACST
Market cap34mUSD
Oct 25, Last price  
3.37USD
Name

Acasti Pharma Inc

Chart & Performance

D1W1MN
XNAS:ACST chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.02%
Rev. gr., 5y
0.00%
Revenues
0k
029,040127,114707,395450,159216,28927,7880000196,000000
Net income
-13m
L-69.71%
0000000000-25,760,000-19,678,000-9,819,000-42,429,000-12,853,000
CFO
-12m
L-22.50%
000000000-22,944,000-14,319,000-17,234,000-15,913,000-12,333,000
Earnings
Feb 10, 2025

Profile

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
URL
https://www.acasti.com/en
IPO date
Mar 31, 2011
Employees
32
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑022015‑02
Income
Revenues
Cost of revenue
10,819
70,339
30,929
Unusual Expense (Income)
NOPBT
(10,819)
(70,339)
(30,929)
NOPBT Margin
Operating Taxes
(1,777)
(9,542)
(648)
Tax Rate
NOPAT
(9,042)
(60,797)
(30,281)
Net income
(12,853)
-69.71%
(42,429)
332.11%
(9,819)
-50.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,338
304
BB yield
-22.48%
-1.48%
Debt
Debt current
75
104
Long-term debt
895
486
Deferred revenue
Other long-term liabilities
4,359
10
Net debt
(23,005)
(26,920)
(43,071)
Cash flow
Cash from operating activities
(12,333)
(15,913)
(17,234)
CAPEX
(22)
(17)
Cash from investing activities
104
13,153
(3,522)
Cash from financing activities
7,359
304
FCF
(8,499)
(61,049)
(30,362)
Balance
Cash
23,005
27,890
43,661
Long term investments
Excess cash
23,005
27,890
43,661
Stockholders' equity
43,881
53,990
96,116
Invested Capital
43,097
40,550
64,914
ROIC
ROCE
EV
Common stock shares outstanding
9,529
7,435
6,140
Price
3.43
24.12%
2.76
-62.30%
7.32
-74.58%
Market cap
32,637
59.07%
20,517
-54.35%
44,947
-36.85%
EV
9,632
(6,403)
1,876
EBITDA
(10,808)
(70,215)
(30,929)
EV/EBITDA
0.09
Interest
911
67,694
224
Interest/NOPBT